RecruitingPhase 3NCT05085171

An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease

A Community-based Phase III, Cluster Randomized Trial of Point-of-care CD4 Testing and Enhanced Screening and Prophylaxis in Advanced HIV Disease

Sponsor

Makerere University

Enrollment

2,400 participants

Start Date

May 4, 2022

Study Type

INTERVENTIONAL

Conditions

The Study Will Focus on Assessing the Survival Benefit on an Enhanced Package of Care for Patients With Advanced HIV Disease

Summary

A community-based Phase III, cluster randomized trial that seeks to determine the 24 week survival with retention in care of point of care CD4 testing with visitect and an enhanced package of screening and prophylaxis for opportunistic infections among patients with advanced HIV disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying an enhanced package of care to reduce death rates in adults with advanced HIV disease who have very low immune cell counts. You may be eligible if... - You are over 18 years old - Your CD4 count (an immune system marker) is below 200 cells per microliter, meaning your HIV is in an advanced stage - You are able and willing to give consent You may NOT be eligible if... - Your viral load (the amount of HIV in your blood) was already very low (under 1,000 copies/mL) in the past 3 months - You are unable or unlikely to attend regular clinic visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREnhanced care package

The intervention is an improved package of care for patients with advanced HIV disease with point of care CD4 testing, more sensitive screening tests for opportunistic infections and more intensive pre-emptive treatment for opportunistic infections

Locations(1)

kisugu health center IV

Kampala, Uganda

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05085171